Kevin Bitterman focuses on creating and investing in companies that translate groundbreaking science into innovative medicines.
Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO), Kinaset Therapeutics, Chroma Medicine, and Curie Therapeutics. He is a co-founder and board member of Disc Medicine, and is chair of the board of Remix Therapeutics and Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic (NASDAQ:MORF) and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). He previously served as a director of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Taris Biomedical (acquired by Johnson & Johnson ) and Vets First Choice (NASDAQ: CVET) among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.
Kevin is active in the life science and healthcare start-up community serving as Chair Emeritus of the New England Venture Capital Association (NEVCA) and as a member of the Harvard Medical School Blavatnik Biomedical Accelerator, Blavatnik Therapeutics Challenge Awards and Q-FASTR Steering Committees. He is also a member of the Isabella Stuart Gardner Museum Board of Advisors. He received a BA in biology, summa cum laude, from Rutgers University before completing his PhD in genetics at Harvard Medical School.
Outside of work Kevin enjoys spending time with his wife and two young daughters. He also enjoys trail running and whiskey, though generally not at the same time.